🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsLab Results & BiomarkersLiver enzymes trending down on GLP-1 — anyone have experience? Page 2

Liver enzymes trending down on GLP-1 — anyone have experience?

DeniseRN_TPA Tue, Apr 15, 2025 at 4:48 PM 23 replies 1,941 viewsPage 2 of 5
raj_cambridge
Member
489
2,123
Jun 2024
Cambridge, MA
Apr 16, 2025 at 5:01 AM#6
DeniseRN_TPA said:
The liver data is among the strongest non-weight findings in the class.

Liver ultrasound comparison for liver and MASH: my hepatologist ordered serial ultrasounds to track NAFLD regression.

Baseline: "Moderate hepatic steatosis, liver span 17.2cm, echogenic texture consistent with fat infiltration"
Month 8: "Mild steatosis, liver span 15.8cm, improved echogenicity"
Month 14: "Minimal to no steatosis, normal liver span 14.5cm, normal echotexture"

My liver literally shrank and de-fattened. The ultrasound tech said she's seen this pattern increasingly in GLP-1 patients and it's remarkable how consistently the fatty liver resolves.

43 13SleepFixSam, PurityPaulOR, MaxMetOK and 40 others
Reply Quote Save Share Report
greg_boulder
Member
345
1,567
Jul 2024
Boulder, CO
Apr 16, 2025 at 9:51 AM#7

One thing that is still open after pete_nash’s answer:

What did you change at the same time, and can you separate the two now?

Last edited: Apr 16, 2025 at 11:51 AM
42 12fiona_VT, denise_HTX, raj_cambridge and 39 others
Reply Quote Save Share Report
VanRx_Mike
Member
678
2,890
May 2024
Vancouver, CA
Apr 16, 2025 at 2:41 PM#8
raj_cambridge said:
Liver ultrasound comparison for liver and MASH: my hepatologist ordered serial ultrasounds to track NAFLD regression.

NASH/MAFLD therapeutic landscape and liver and MASH: GLP-1 agonists are emerging as potential first-line NASH therapy. The Phase 2b data for semaglutide showed 59% NASH resolution (vs 17% placebo) with 43% achieving fibrosis improvement[1].

Mechanism: GLP-1R activation reduces hepatic lipogenesis, increases fatty acid oxidation, reduces hepatic inflammation, and may directly reduce hepatic stellate cell activation (fibrosis pathway).

With resmetirom (thyroid hormone receptor agonist) recently approved for NASH, the field is evolving rapidly. Combination approaches (GLP-1 + resmetirom) are being explored.

References:
[1] Newsome PN, et al. N Engl J Med. 2021;384(12):1113-1124.
41 11Admin, Dr.Martinez, mike_mod and 38 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
DeniseRN_TPA
Member
345
1,567
Aug 2024
Tampa, FL
Apr 16, 2025 at 7:32 PM#9

Closing the loop on my own question.

Closing the loop. The answer turned out to depend on the detail I had left out of the opening post, which is a lesson about how to ask rather than about the subject.

Last edited: Apr 16, 2025 at 10:32 PM
40 10LindaRN_retired, tommy_boulder, hyun_seoul and 37 others
Reply Quote Save Share Report
stefan_berlin
Member
234
1,123
Oct 2024
Berlin, DE
Apr 17, 2025 at 6:47 PM#10
VanRx_Mike said:
NASH/MAFLD therapeutic landscape and liver and MASH: GLP-1 agonists are emerging as potential first-line NASH therapy.

Fair, and it stops being fair at the extremes. The middle of the range is well understood; the ends are where the honest answer is that nobody knows.

38 11TrialTracker_MD, JennaRN, LabKate and 35 others
Reply Quote Save Share Report

Similar Threads

Optimal lab testing frequency on GLP-1 — evidence-based schedule5 replies
A1C from 7.2 to 5.1 — my bloodwork transformation19 replies
Thyroid function monitoring on GLP-1 — TSH and free T4 trends3 replies
Lipid panel improvements mega-thread — share your numbers19 replies
Liver enzymes trending down on GLP-1 — ALT/AST normalization17 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register